BASSAM MATTAR, MD
Hematology & Oncology Physician · WICHITA, KS
Individual Active NPI 1053372649
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,637 | 740,012 | $57,175,876 | $17,313,927 | $13,800,548 |
| 2023 | 1,543 | 656,034 | $35,068,399 | $12,903,524 | $10,284,753 |
| 2022 | 1,432 | 684,309 | $24,437,414 | $11,556,336 | $9,198,393 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 137,640 | $0 | $0 |
| J9271 | Injection, pembrolizumab, 1 mg | 65,000 | $56 | $45 |
| J0185 | Injection, aprepitant, 1 mg | 50,050 | $2 | $1 |
| J0897 | Injection, denosumab, 1 mg | 38,940 | $26 | $21 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 38,880 | $49 | $39 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 33,750 | $1 | $1 |
| J9299 | Injection, nivolumab, 1 mg | 32,080 | $31 | $25 |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | 31,400 | $6 | $4 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 23,390 | $3 | $2 |
| J9267 | Injection, paclitaxel, 1 mg | 15,334 | $0 | $0 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 14,100 | $0 | $0 |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 13,068 | $26 | $21 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Hematology & Oncology Physician | 207RH0003X | ✓ | 0427872 | KS |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Hematology & Oncology Physician providers in Kansas
- NPI 1841251394
- NPI 1821249137
- NPI 1972721348
- NPI 1043272305
- NPI 1336451665
- NPI 1528263043
- NPI 1750777959
- NPI 1528029147
See all Hematology & Oncology Physician providers in Kansas →
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.